Portfolio Growth Recent investments in Kasvu Therapeutics and Actithera show active dealmaking and support for companies advancing toward clinical development. Sales teams offering clinical trial services, regulatory expertise, or specialist CRO capabilities may find timely opportunities.
Fund Deployment Hadean Capital II closed with €144 million, providing capital for continued investment across European life sciences. Fund administration, portfolio analytics, deal sourcing, and investment management solutions could be relevant, subject to the fund’s current deployment stage.
Team Expansion The appointment of Georgina Askeland as Board member and Principal signals a growing investment team and added expertise in neuropsychiatric innovation. Executive recruitment, research intelligence, and investor or board workflow tools may be useful prospects.
European Reach With offices in Oslo and Stockholm and investments spanning Europe, Hadean operates across multiple markets and healthcare systems. Cross-border legal, tax, compliance, and market-access services could help support its investment activity and portfolio companies.
Digital Operations The company uses AWS, Microsoft 365, WordPress, and Mailgun, indicating a cloud-based business and communications setup. Cybersecurity, cloud optimization, CRM, and investor communications offerings may be relevant, though the listed stack alone does not confirm specific needs.